Bio-Rad Acquires Celsee, Inc.
April 9, 2020
Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.
- Buyers
- Bio-Rad Laboratories, Inc.
- Targets
- Celsee, Inc.
- Industry
- Biotechnology
- Location
- Michigan, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Discovery Life Sciences Acquires ReachBio Research Labs
April 11, 2023
Biotechnology
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
Molecular Devices Acquires Cellesce Ltd
December 6, 2022
Biotechnology
Molecular Devices, a life-science instrumentation company, has acquired Cellesce Ltd, a Cardiff-based developer and manufacturer of patient-derived organoids (PDOs) for large-scale drug screening. The deal expands Molecular Devices' 3D biology capabilities and combines Cellesce's industrial-scale PDO production with Molecular Devices' automated organoid screening platforms to accelerate adoption of physiologically relevant cell models in drug discovery.
-
CellCarta Acquires Biogazelle
December 14, 2021
Biotechnology
CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.
-
PerkinElmer Acquires Nexcelom Bioscience for $260M
May 13, 2021
Medical Devices
PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.
-
Clinical Reference Laboratory Acquires Confirm BioSciences
December 9, 2020
Healthcare Services
Clinical Reference Laboratory (CRL), a large privately held clinical testing laboratory, has acquired Confirm BioSciences, a San Diego–based provider of screening tools and consumer-facing testing products. The acquisition will have Confirm operate as a subsidiary and is intended to expand CRL's lab testing and R&D capabilities while leveraging Confirm's large retail/customer base and COVID-19 testing pipeline.
-
PerkinElmer Acquires Cisbio Bioassays from Abénex
April 26, 2019
Biotechnology
PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.